Endothelin Receptor Antagonists in Cancer Therapy

Author： Lalich Mihailo   McNeel Douglas   Wilding George   Liu Glenn  

Publisher： Informa Healthcare

ISSN： 0735-7907

Source： Cancer Investigation, Vol.25, Iss.8, 2007-10, pp. : 785-794

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

The Endothelin Receptor: A Novel Target for Anticancer Therapy

By Pirtskhalaishvili G.   Nelson J.B.  

American Journal of Cancer, Vol. 1, Iss. 2, 2002-02 ,pp. : 81-91

Adis International

Access to resources Recommend Favorite

GnRH Agonists and Antagonists in Cancer Therapy

By  

Current Medicinal Chemistry - Anti-Cancer Agents, Vol. 3, Iss. 6, 2003-11 ,pp. : 399-410

Bentham Science Publishers

Access to resources Recommend Favorite

Death Receptor Signaling in Cancer Therapy

By  

Current Medicinal Chemistry - Anti-Cancer Agents, Vol. 3, Iss. 4, 2003-07 ,pp. : 253-262

Bentham Science Publishers

Access to resources Recommend Favorite

Epidermal Growth Factor Receptor Antagonists in Pancreatic Cancer: What is Their Role?

By Tang Patricia A.   Moore Malcolm J.  

American Journal of Cancer, Vol. 5, Iss. 4, 2006-01 ,pp. : 213-221

Adis International

Access to resources Recommend Favorite

VIP receptor antagonists and chemotherapeutic drugs inhibit the growth of breast cancer cells

By Moody T.W.  

Breast Cancer Research and Treatment, Vol. 68, Iss. 1, 2001-07 ,pp. : 55-64

Springer Publishing Company

Access to resources Recommend Favorite